List of searches and offers

If you want to publish your search or offer – please press “MY NEW PARTNER SEARCH” or “MY NEW PARTNER OFFER” at the left and fill the form.
After the form is correctly filled and submitted, the Euronanomed website administrator will check and publish your search or offer.
If you are willing to change something in the text that you have allready filled and submitted – please fill the form once again with a correct text and send an email to administrator with an explanation of the change (juozas.lapienis@euronanomed.net).

Type: Search

Type: Offer

Offer
Partner Role:
Partner
Topic of the offer:
The title: A nucleotide-modified RNA-aptamer, selected to the self-surface of human B-cell lymphoma cell, as the targeting moiety for delivery of therapeutic molecules.
We have generated nucleotide-modified RNA-aptamers (nmRNA-aptamers) (80 - 100 nt oligonucleotides) that recognize the cell-surface molecules of malignant B-cell lymphoma (Burkitt lymphoma, BL) cells, using the Whole-Cell SELEX method modification (Cell-SELEX-FA) elaborated by us previously. Viability tests have demonstrated that one of the selected nmRNA-aptamers (at concentration 4.0 µM) inhibited cell proliferation of the all studied highly malignant CD10+ BL lines (n=5) from 56% up to 99%. The same nmRNA-aptamer (nmRNA-apt) was inactive in T-cell lymphoma cell lines and normal donor lymphocytes. Soft-Agar-Growing Test has also demonstrated significant inhibition of the cell-colony formation of the CD10+ BL lines by this nmRNA-apt. We assumed that the selected nmRNA-aptamer can be suggested as the carrier molecule to target malignant B cells for delivery of therapeutic molecules.
The aim of the WP#: investigation of potential therapeutic application of the generated nmRNA-aptamer as the targeting moiety for delivery of therapeutic molecules in human B-cell lymphoma model.
The methodology will include the study: (1) using the panel of human high-malignant B-cell lymphoma cell lines (BCLs) versus the EBV-immortalized non-malignant lymphoblastoid B-cell lines (LCLs); (2) on the panel of human cancer cell lines of different tissue origin and (3) using the peripheral blood samples from healthy individuals and patients with B-cell lymphomas, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
Expected results of the WP#: to work out the protocol (dozes per malignant cell, input incubation time-schedule) by which both the highest BCL cell-proliferation blocking effect and the lowest toxic effect for non-malignant B cells will be achieved in order to suggest the new developed strategy, based on the application of the nmRNA-aptamer complex and the elaborated protocol, for the treatment of patients with high-grade aggressive B-cell lymphomas.
Other information:
Competences offered:
Task 1.1. Production of nmRNA-apt and the control nmRNA-NN (random sequences), using a previously developed protocol, in amounts needed for generation of nmRNA-aptamer complexes and the following in vitro experiments;
Task 1.2. Verification of specific cell-proliferation blocking property of the prepared nmRNA-apt and the control nmRNA-NN by MTT test, using reference cell lines (B-cell lymphoma, T-cell lymphoma, and EBV-immortalized non-malignant lymphoblastoid B-cell lines, LCL) and the panel of human cancer cell lines of different tissue origin (monocytic, cervix, breast, colon, lung, kidney, stomach);
Task 2.1. To work out the protocol (dozes per cell, input incubation time-schedule) by which both the highest B-cell lymphoma cell-proliferation blocking effect and the lowest toxic effect for non-malignant B cells will be achieved for the nmRNA-aptamer complexes, in comparison with the free nmRNA-apt and the control nmRNA-NN, using cell lines (B-cell lymphoma, T-cell lymphoma, and LCL);
Task 2.2. (Optional, financing-depended) Evaluation of the in vivo toxicity in mice (biodistribution and tissue toxicity) of the nmRNA-aptamer complexes, in comparison with the free nmRNA-apt and the control nmRNA-NN;
Task 3. Verification of the malignant-B-cell specificity of the nmRNA-aptamer complexes, in comparison with the free nmRNA-apt and the control nmRNA-NN, using the peripheral blood of patients with B-cell lymphomas, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), applying the aptamer 5’-end FITC-labeling and the multiparameter flow cytometry analyses (BD FACSAriaIII).
Offer
Partner Role:
Partner
Topic of the offer:
Nobel Pharmaceuticals is one the leading pharmaceutical company in Turkey. We are looking for a partnership for upcoming EuroNanoMed3 call.
We are searching for a partnership opportunities for development and usage of nanocarrier systems for one of the existing mammalian cell based biotechnological drugs in the market. We can contribute for the production and nanocarrier based formulation of biotechnological drugs in GxP environment. Our current capabilities could enable validation in relevant areas which enables co-development of TRL 3-6 projects in pharmaceutical drug field.

Other information:
  • First name, Surname: Selim SÜLEK
  • Institution/organisation: Nobel Pharmaceuticals
  • Country: Turkey
  • E-mail: selim.sulek@nobel.com.tr
  • Website: www.nobel.com.tr
Competences offered:
As Nobel, we are working on mammalian cell based production of monoclonal antibodies and protein for therapeutic usage. We could be a part in development about nanocarriers, bioreactor, newly developed purification systems and process based on microfluidics, artificial intelligence in therapeutic areas. We also want to be a part of project in nanotechnology field related with life science and/or pharmacy. We can have direct contribution for comparison of traditional methods vs newly developed methods and also full characterization of end products of mammalian cell based products. We could be a partner for projects that are TRL 3-6 level.
Briefly What We can Offer:
• Upstream and Downstream Process Development
• Antibody and protein characterization
• Epitope Mapping, interaction and kinetic with SPR and/or Octet Systems.
• Physicochemical and biochemical analysis and method development
• GMP Production
• Industrial Cell Line
• Ready to use Upstream and Downstream process for several molecules
• Collaborating in developing new technology or advancement in available one.
• Testing of new technology or devices.
• Re-development of process and procedures for better economical and health profits
Offer
Partner Role:
Partner
Topic of the offer:
Topic of the offer:
Field of interest:
1. Skin regeneration
2. bone and cartilage repair/regeneration,

MAJOR RESEARCH INTEREST OF THE GROUP
• Biocompatibility assessment of materials proposed for bone and skin engineering
• The potential of MSC secretome for wound and osteo-articular regenerative therapy
• Development of skin and bone 3D organotypic cultures for in vitro study of therapeutic compounds
Other information:
  • First name, Surname: Irina Titorencu
  • Institution/organisation: Institute of Cellular Biology and Pathology Nicolae Simionescu
  • Country: Romania
  • E-mail: irina.titorencu@icbp.ro
  • Website: www.icbp.ro
Competences offered:
• Cell culture techniques
• Biocompatibility assessment for organic and inorganic materials
• 2D and 3D culture systems
• Histological processing and staining
• Ultracentrifugation techniques for exosomes isolation
• Fluorescence microscopy
• Molecular biology (Western blot, PCR, RT-PCR, qPCR)
Offer
Partner Role:
Partner
Topic of the offer:
Topic of the offer:
Field of interest: cardiovascular research

MAJOR RESEARCH INTEREST OF THE GROUP
• Modulation of angiogenesis
• Regenerative therapy
• Stem cells
Other information:
  • First name, Surname: Ana Maria Rosca
  • Institution/organisation: Institute of Cellular Biology and Pathology Nicolae Simionescu
  • Country: Romania
  • E-mail: ana-maria.rosca@icbp.ro
  • Website: www.icbp.ro
Competences offered:
• Mesenchymal stem cells
• Biocompatibility assessment
• 2D and 3D culture systems
• Histological analysis
• Fluorescence microscopy, confocal microscopy
• Molecular biology (Western blot, PCR, RT-PCR, qPCR, transfections)
• Biochemistry techniques
• In vivo angiogenesis assay
Offer
Partner Role:
Partner
Topic of the offer:
- Biocompatible and biodegradable polymeric nanocarriers for Regenerative medicine and
Target delivery.
- Biocompatible and biodegradable polymeric nanocarriers modified with metallic
nanoparticles for Theragnostics (Regenerative medicine, Target delivery, and diagnostics)
- Metallic nanoparticles with surface modifications for Drug Delivery, Diagnostics, and
Theranostics.
Other information:
  • First name, Surname: Jose Luis Muñoz Gómez
  • Institution/organisation: LEITAT
  • Country: España
  • E-mail: jlmunoz@leitat.org
  • Website: https://www.leitat.org/
Competences offered:
• Rational design, synthesis, and characterization of smart nanocarriers regarding the route of
administration of the final formulation.
• Design, synthesis, and characterization of biofunctionalized inorganic nanoparticles with
specific responses for medical diagnosis, therapy, theranostics, and biosensing
• Release studies under relevant reconstructed biological fluids.
• Stability testing based on durability sustained release and transformation of the
nanosystems and the final formulations in biologically relevant environments.
Offer
Partner Role:
Partner
Topic of the offer:
- animal models of stroke, intracerebral hemorrhage, and gliobastoma (in mice or rat) - in vitro, and in vivo MRI studies for diagnosis and therapy (9.4 T, Bruker System) - characterization of new contrast agents for MRI and cell tracking
Other information:
  • First name, Surname: Ramón Iglesias-Rey
  • Institution/organisation: Clinical Neurosciences Research Laboratory, Health Research Institute of Santiago de Compostela (IDIS)
  • Country: Spain
  • E-mail: ramon.iglesias.rey@sergas.es
  • Website: www.linc-stg.eu/contactar.aspx
Competences offered:
We offer the possibility to participate in different studies through the following knowledge and experience 1) Experimental and Behavioral Animal Unit: Animal housing for rodents with all necessary resources to house 150 rats and 60 mice. 2) Surgery Unit: Four fully equipped surgery rooms for rodents, with gaseous anesthesia, stereotaxic frames, surgery microscopes, electrocoagulation, Doppler blood flow-meter, infusion pumps, thermal control units, etc. 3) Tissue Preservation Unit: -80ºC preservation cabins for preservation of tissue samples, cryostats for preparation of histological sections, and a reverse phase fluorescence microscope for immuno-histochemical analysis 4) Cell Culture Unit: Laminar flow cabin, incubator, experimental ischemia system (chamber of oxygen and glucose deprivation of cell cultures), inverted microscope, cryogenic preservation systems a -80ºC, access to confocal microscopy. 5) Nanoparticle Processing Unit: reactor, a shaker and a sounding bath for processing of iron nanoparticles. Rotavapor coupled to extruder for the elaboration of liposomes. 6) Molecular Imaging Unit (MRI): with a state-of-the-art MRI system of 9.4 Tesla (Bruker Biospin) for rodents, equipped with animal monitoring systems. The use of this platform in its different variants: anatomical, and molecular imaging spectroscopy allows progression of the disease, noninvasive (in vivo) and longitudinal time-related processes related to neurovascular diseases such as plasticity, reorganization or neurorepair and functional recovery in animal models. Neuroimaging and Cardiac magnetic resonance imaging are available for this system.
Offer
Partner Role:
Partner
Topic of the offer:
- skin tissue engineering, 3D culture (tumor spheroids) - extracellular matrix remodeling - electroporation or polymeric micelles for drug delivery
Other information:
  • First name, Surname: Laure Gibot
  • Institution/organisation: CNRS IMRCP (academic)
  • Country: France
  • E-mail: gibot@chimie.ups-tlse.fr
  • Website: http://imrcp.ups-tlse.fr/
Competences offered:
original human skin tissue engineering based on self-assembled approach, so no exogenous material, rich in endogeneous extracellular matrix. Studies at tissue scale (skin substitute or tumor spheroids) Chemical and biological tools to analyse extracellular matrix remodelling drug delivery via physical approach (electroporation) or chemical ones (self-assembled polymeric micelles)
Offer
Partner Role:
Partner
Topic of the offer:
Despite their functional similarity to protein antibodies, oligonucleotide aptamers have many unique properties that are suitable for clinical applications and industrialization. Aptamers can be use in fields such as biomarker discovery, in vitro and in vivo diagnosis, precisely controlled drug release and targeted therapy. Aptamers have been used successfully in therapy (Pegaptanib), in diagnostic platforms and as a biotechnological tool.
Other information:
  • First name, Surname: Miguel Moreno
  • Institution/organisation: Aptusbiotech
  • Country: Spain
  • E-mail: miguel.moreno@aptusbiotech.com
  • Website: http://en.aptusbiotech.com/
Competences offered:
Aptus Biotech is a biotech start-up R&D performing SME whose main goal is the development of new biotechnological applications based on aptamer technology. Aptamers are artificial nucleic acid ligands (short single-stranded RNA or DNA) that present high association constants with target proteins, relatively easy and reproducible production and labelling, cost-effectiveness and stability during long-term storage. Aptamer technology is an innovative alternative and much less known than that of monoclonal antibodies. This technology provides multiple applications in biotechnology, health, agriculture-food industry and other sectors. Specifically, as a successful case in aptamers R&D, Aptus carried out the initial stages of the development and characterization of an aptamer against TLR4 . Firstly patented by the company (PCT/EP2015/064277), in 2017, AptaTargets purchased the molecule and initiated the ApTOLL program towards the treatment of acute ischemic stroke. Currently, the molecule is in clinical trials phase IIa.
Offer
Partner Role:
Partner
Topic of the offer:
Clinical center specializing in cancer care, along with preclinical oncology research facilities through partner institution (IFOM). Interested in participating in preclincial, and clinical studies into biological mechanisms, as well as diagnostic and therapeutic nanomed applications in oncology.
Other information:
  • First name, Surname: Paul Summers
  • Institution/organisation: Istituto Europeo di Oncologia
  • Country: Italy
  • E-mail: paul.summers@ieo.it
  • Website: www.ieo.it
Competences offered:
A range of cancer patient groups in care, with paritcularly large populations of breast and prostate cancer patients. A leader in low dose CT screening, prostate, breast and whole-body MRI, and mammography services. Specialist robotic surgery and radiotherapy services.
Offer
Partner Role:
Partner
Topic of the offer:
Tissue engineering, coatings
Other information:
  • First name, Surname: Juan Antonio Ruiz Fuentes
  • Institution/organisation: Nadetech Innovations
  • Country: España
  • E-mail: juanan.ruiz@nadetech.com
  • Website: www.nadetech.com
Competences offered:
-Customization of coating devices based on several techniques
-NovaSpider: 3D bioprinting and more (www.novaspider.com)
Offer
Partner Role:
Partner
Topic of the offer:
Magnetism of nanostructures, with particular reference to magnetic nanoparticles and nanocarriers for nanomedicine applications (magnetic hyperthermia, drug delivery and release, tissue regeneration).
Other information:
  • First name, Surname: Lucia Del Bianco
  • Institution/organisation: Department of Physics and Earth Sciences - University of Ferrara
  • Country: Italy
  • E-mail: lucia.delbianco@unife.it
  • Website: http://docente.unife.it/lucia.delbianco
Competences offered:
- Expertise in the study of magnetic hysteretic properties, magnetic configuration and spin canting, magnetization processes, thermal stability and superparamagnetism, magnetic dipolar and exchange interactions.
- Expertise in the phenomenology of magnetic heating from magnetic nanoparticles subjected to an alternating magnetic field.
- Experience in the use of SQUID magnetometer, in Mössbauer spectroscopy and calorimetric and thermogravimetric analysis (DSC-TGA).
Offer
Partner Role:
Partner
Topic of the offer:
Diagnostics or drug delivery
Other information:
  • First name, Surname: Aristeidis Bakandritsos
  • Institution/organisation: Regional Centre of Advanced Technologies and Materials
  • Country: Czech Republic
  • E-mail: a.bakandritsos@upol.cz
  • Website: https://www.rcptm.com/
Competences offered:
We offer:
-Imaging agents (MRI, photoacoustic, fluorescent, PET/SPECT)
-Nanomaterials for electrochemical and fluorescent sensing platforms
-Nanotheranostics and photothermal therapy agents
-Antibacterial agents against resistant bacteria
Offer
Partner Role:
Partner
Topic of the offer:
Elvesys is a French innovative SME dedicated to flow management and microfluidic instrumentation. We design the microfluidic system that will meet the specific needs of your application (e.g. innovative health care, point of care testing, diagnosis, drug testing, …), and automate fluid handling tasks for your project. We already bring our expertise to more than 30 European projects, we would be glad to help you to develop the innovative microfluidic setup that fits your project needs.
Other information:
  • First name, Surname: Noémi Thomazo
  • Institution/organisation: Elvesys
  • Country: France
  • E-mail: partnership@elvesys.com
  • Website: https://www.elveflow.com
Competences offered:
Microfluidics
Flow control at microscale
Lab-on-chip for diagnostics
Organ-on-chip to study disease mechanisms and test new drugs
Offer
Partner Role:
Partner
Topic of the offer:
Elvesys is a French innovative SME specialized in microfluidic instrumentation and flow control. We are interested to join a consortium of the upcoming EuroNanoMed3 call. In particular, we can contribute to the development of lab-on-chips for analysis of chemicals, or organ-on-chip platforms to evaluate the toxicity of pollutants on health.

We will be happy to discuss further!
Other information:
  • First name, Surname: Christa Ivanova
  • Institution/organisation: Elvesys SAS
  • Country: France
  • E-mail: christa.ivanova@elvesys.com
  • Website: www.elveflow.com
Competences offered:
Microfluidics, Lab-on-chip, Organ-on-chip, Dissemination, Single Cell Encapsulation, Parallelization of Experiments, Miniaturization of Laboratory Assays
Offer
Partner Role:
Partner
Topic of the offer:
Mammalian cell transfection systems, suitable for the therapeutic protein production. Our transfection method is based on cell penetrating peptide (CPP) mediated delivery of nucleic acid and is applicable to mammalian cell factories (large scale protein production) with much higher efficacies compared to the current state-of-the-art commercial protein production platforms.
Other information:
Competences offered:
Chemical biology: Chemical synthesis of peptide / polymer -based transfection components.
Cell biology: Transfection in mammalian cell cultures. Cell culture screening models, applicable in the context of large scale therapeutic protein production.
Offer
Partner Role:
Partner
Topic of the offer:
- development of recombinant protein binders using selection from highly complex scaffold libraries as high-affinity ligands for in vitro and vivo diagnostics
- development of non-cognate protein ligands targeted to broadly neutralizing antibodies as viral epitope mimetics useful as immunogens for vaccine development
- generation of protein blockers with neutralizing potential
Other information:
  • First name, Surname: PETR MALY
  • Institution/organisation: Institute of Biotechnology of the Czech Academy of Sciences, v.v.i.
  • Country: Czech Republic
  • E-mail: petr.maly@ibt.cas.cz
  • Website: https://www.ibt.cas.cz/en/
Competences offered:
- selection of protein scaffold variants using ribosome display from highly complex combinatorial libraries (scaffolds with randomized loops, beta-sheets or three helix bundle)
- biophysical, biochemical and functional characterization of binding proteins
- protein engineering with directed evolution or rational design
- modification of proteins, affinity maturation, tailor-made proteins
Offer
Partner Role:
Partner
Topic of the offer:
Smartphone-based diagnostics for point-of-care testing in various matrices
Other information:
  • First name, Surname: Aristeidis Tsagkaris
  • Institution/organisation: University of Chemistry and Technology in Prague
  • Country: Czech Republic
  • E-mail: tsagkara@vscht.cz
  • Website: https://uapv.vscht.cz/?jazyk=en
Competences offered:
• Biosensors: Methods development, validation and benchmarking
• 3D-printing, fabrication of lab-on-a-chip devices with integrated functions
• Use of smartphones as analytical detectors for ubiquitous sensing
• Instrumental analysis for example liquid chromatography coupled to high resolution mass spectrometry, for biosensor result confirmation
Offer
Partner Role:
Partner
Topic of the offer:
- nano or microstructured wound dressings for chronic wounds healing based on nanofiber mats and lipide particles for controled release kinetics
- semiproduction machine for microfluidic preparation of lipide drug capsules
- impragnation of implants with different type of active substance (and its structures)
- antibacterial surfaces based on silver particles
Other information:
  • First name, Surname: Taťána Fenclová
  • Institution/organisation: ING Medical s.r.o.
  • Country: Czech Republic
  • E-mail: tatana.fenclova@ingmed.cz
  • Website: www.ingmed.cz
Competences offered:
- wound dressings with active formulation with encapsulated active substance
- spray atomization of nano/microparticel dispersions and liquids on modulate production line
- electrospinning of nanofiber mats for wound covers
Offer
Partner Role:
Partner
Topic of the offer:
Testing of interaction of different nanomaterials - nanoparticles and surfaces with nanotopoghrapy - with different cell types (primary cells, cell lines - immune cells, bone cells, mesenchymal stem cells).
Test of new implants.
Test of nanoparticles for delivery or for modulation of immune system.
Other information:
Competences offered:
Cell culture tests of cell viability, metabolism, adhesion, expression, release of cytokines, exosomes using advanced techniques - confocal and electron microscopy, flow cytometry analysis, biochemical and molecular biological methods
Offer
Partner Role:
Partner
Topic of the offer:
Fullerene nanomaterials for CRISPR-Cas9 delivery
Other information:
Competences offered:
We are looking for partners in the field of genome editing. We offer engineered fullerene nanomaterials which are already active for siRNA transfection. We are looking for biologically oriented partners with expertise in CRISPR-Cas9 techniques.
Offer
Partner Role:
Partner
Topic of the offer:
Trace and ultra-trace metals (total and speciation) analysis, Nanomaterials (NMs) characterization (nanoparticles and nanomedicines), analytical method development and validation
Other information:
  • First name, Surname: Menta Mathieu
  • Institution/organisation: Ultra Traces Analyses Aquitaine - UT2A / ADERA
  • Country: France
  • E-mail: mathieu.menta@univ-pau.fr
  • Website: www.ut2a.fr
Competences offered:
The analytical equipment of the laboratory is composed of Mass Spectrometers and Atomic Emission Spectrometers by Induced Plasma Coupling (ICP-MS and ICP-AES), associated separation systems (High Performance Liquid Chromatography / HPLC, Gas Chromatrography / GC), and equipment dedicated to the characterization of NMs such as DLS, AF4-MALS-ICPMS and spICP-MS.

For nearly ten years, UT2A has acquired skills in NMs characterization in the fields of food, cosmetics, environment and health. The laboratory has thus been involved in various research projects related to quality assurance or quality control (QUACHA, TRAP, SWIFT), speciation analysis (ELISA) and nanomedicines (NANOPILOT - H2020).

Since 2010, UT2A has set up a quality environment based on the Good Laboratory and Manufacturing Practices (GLP/GMP). This standard has been implemented within UT2A through various concrete actions such as the drafting of a quality assurance manual, the traceability of samples, analyses and results, the metrological control of laboratory equipment. UT2A is regularly audited by different companies. These audits allow UT2A to work according to a high-performance quality system in continuous improvement.

Competences offered:
- Multi-dimensional physico-chemical characterization of polymers and nanoformulations by A4F-UV-MALS-(RI or ICPMS) online : granulometry (size, size distribution), shape, aggregation state, stability, encapsulation efficiency, chemical composition
- Determination of size and concentration of metallic nanoparticles by Single particle ICPMS
- Granulometry by DLS according to ISO reference document.
- Analytical method development and validation expertise in a nearly GLP implemented environment together with external QA audits.
- Trace metals impurities in pharmaceutical products according to ICHQ3D
- Speciation and trace metal analysis by HPLC and GC-ICPMS